Clinical trial
Phase II Study of RFS 2000 in Relapsed NSCLC
NCT00005872 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of RFS 2000 in Relapsed NSCLC
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 31, 1999
- Completion date
- April 30, 2004
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
lung cancer